Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030 · cited 4×
“, infusion set error) rather than automated insulin delivery function [37,45,76,78].”
BackgroundResultInfluentialEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894 · cited 2×
“However, SAP still could not improve severe hypoglycemia [15,58] and so the group developed an SAP with an LGS function that automatically stops insulin infusion in the event of Fig.”
BackgroundMethodFeig, D. S., Donovan, L. E., Corcoy, R., Murphy, K. E., Amiel, S. A., Hunt, K. F., Asztalos, E., Barrett, J. F. R., Sanchez, J. J., de Leiva, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32400-5 · Cited by 803
SEARCH for Diabetes in Youth Study Group (2006) · Pediatrics · doi:10.1542/peds.2006-0690 · Cited by 726
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“2013 [16] Medtronic Medtronic Enlite Minimed 530G Minimed 530G RCT, parallel 247 16–70 Home 3 months LGS SAP SAP Nocturnal hypoglycemic events: 1.”
BackgroundSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 6×
“For single-hormone HCL studies, although each study presented a different form, TBR <54 or <50 mg/dL were significantly improved in HCL compared to CSII (Florence system, TBR <50 mg/dL, 0.3% vs. 1.0%, P <0.01; Minimed 670G, TBR <54 mg/dL, 0.2% vs. 0.9%, P <0.01) [24,77].”
BackgroundMethodInfluentialExercise-stimulated glucose uptake — regulation and implications for glycaemic control
Sylow, L., Kleinert, M., Richter, E. A., & Jensen, T. E. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.162 · Cited by 498 · cited 1×
“However, because of the time gap between the onset of insulin action and the rise in blood glucose, single-hormone APS users remain at high risk of developing hypoglycemia after meals, especially if they exercise [102].”
BackgroundYeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493
Cappon, G., Vettoretti, M., Sparacino, G., & Facchinetti, A. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0121 · Cited by 477
Cited by
Zeng, B., Gao, L., Yang, Q., Jia, H., & Sun, F. (2023) · Diabetes Care · doi:10.2337/dc23-0504 · Cited by 100
Moon, S. J., Kim, K., Lee, W. J., Lee, M. Y., Vigersky, R., & Park, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14852 · Cited by 69
Self-citationPemberton, J. S., Wilmot, E. G., Barnard‐Kelly, K., Leelarathna, L., Oliver, N., Randell, T., Taplin, C. E., Choudhary, P., & Adolfsson, P. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14962 · Cited by 44
Kim, J. Y., Kim, S., & Kim, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0804 · Cited by 13
Metadata
- Authors
- Moon, S. J., Jung, I., & Park, C.-Y.
- Venue
- Diabetes & Metabolism Journal
- Publisher
- Korean Diabetes Association
- Published
- 2021-11-30
- Volume
- 45
- Issue
- 6
- Pages
- 813-839
- ISSN
- 2233-6079 (ISSN-L)
- 2233-6087
- OpenAlex
- W3215260405
- Cited by
- 98
- References
- 40
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence. https://app.cochat.ai/papers/10.4093/dmj.2021.0177
- The paper
- Moon, S. J., Jung, I., & Park, C.-Y. (2021). Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2021.0177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.